CVS Health Reports Steep Profit Decline Driven by $5.7B Goodwill Impairment and $1.5B Litigation Charges in 2025 Annual Report
CVS sits 38% above its 52-week low of $53.36.
Summary
CVS Health's 2025 annual report details a 61.7% drop in net income and a significant EPS decline, primarily due to a $5.7 billion goodwill impairment on its Health Care Delivery unit and over $1.5 billion in litigation charges, alongside strategic exits and Medicare rate pressures.
Key Events · Earnings and Guidance · CVS
-
Massive Goodwill Impairment
The company recorded a $5.7 billion goodwill impairment charge in Q3 2025 related to its Health Care Delivery reporting unit (Oak Street Health and Signify Health), driven by lower financial projections, reduced new clinic openings, and planned closures of existing Oak Street Health clinics.
-
Significant Litigation Charges
CVS Health incurred $1.2 billion in legacy litigation charges from two court decisions (Omnicare False Claims Act, PBM practices) and an additional $320 million opioid litigation charge, bringing the total opioid accrual to $4.0 billion.
-
Sharp Decline in Profitability
Despite a 7.8% increase in total revenues to $402.067 billion, operating income decreased 45.3% to $4.660 billion, and net income attributable to CVS Health plummeted 61.7% to $1.768 billion, with diluted EPS falling from $3.66 to $1.39.
-
Strategic Exits and Medicare Headwinds
The company exited the ACO REACH program and divested MSSP operations, incurring a $288 million pre-tax loss. Medicare Advantage star ratings declined from 88% to 81% for 4.0+ star plans, and proposed 2027 Medicare Advantage payment rates show a minimal 0.09% increase (excluding risk score trend).
Analysis · CVS · Trade & Services
CVS Health's annual report reveals a challenging 2025, marked by a substantial decline in profitability despite revenue growth. The core issue stems from a massive $5.7 billion goodwill impairment related to its Health Care Delivery unit (including Oak Street Health and Signify Health acquisitions), signaling significant underperformance and revised growth expectations for these strategic investments. Additionally, the company incurred over $1.5 billion in litigation charges, highlighting ongoing legal and regulatory pressures from past business practices and opioid-related matters. The deconsolidation of Omnicare, LLC due to bankruptcy further underscores operational challenges. Investors should be concerned about the profitability of recent acquisitions, the persistent legal overhang, and the potential for continued pressure on Medicare Advantage rates and star ratings, which could impact future earnings.
At the time of this filing, CVS was trading at $73.75 on NYSE in the Trade & Services sector, with a market capitalization of approximately $96.2B. The 52-week trading range was $53.36 to $85.15. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.